Practice

Prescribers’ Perspectives on Strategies for Increasing Biosimilar Adoption

December 17th 2022

By Deana Ferreri, PhD

Article

Despite recent steps taken by the FDA to streamline approvals and increase availability for biosimilars, biosimilar adoption has been slow and primarily driven by payers in the United States, signaling that more needs to be done to encourage adoption, according to experts at a virtual workshop hosted by the FDA and the University of Maryland.

Dr Ryan Haumschild Discusses Stakeholder Collaboration to Boost Biosimilar Adoption

December 15th 2022

By Skylar Jeremias

Video

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, tackles how stakeholders can collaborate and utilize market data to effectively boost biosimilar uptake.

Prime Therapeutics Completes Acquisition of Magellan Rx Management

December 6th 2022

By Skylar Jeremias

Article

Prime Therapeutics has officially acquired Magellan Rx Management, a popular pharmacy benefit manager (PBM) in the specialty pharmacy space. The acquisition was announced in May 2022 and includes the acquisition of Magellan Rx’s specialty, PBM, and government pharmaceutical and Medicaid business segments.

ACMA Begins Board Certification Program for Biologics, Biosimilars Specialists

December 5th 2022

By Skylar Jeremias

Article

The Accreditation Council for Medical Affairs (ACMA) is launching a new program for health care professionals to become Board Certified Biologics and Biosimilars Specialists.

Dr Ivo Abraham Column: 1 Billion People Can Access Biosimilars; What About the Other 7 Billion?

November 30th 2022

By Ivo Abraham, PhD

Article

Now that the world population has reached 8 billion, Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, took a look at how high-income countries can increase accessibility to livesaving medicines to the 7 billion people who have limited access to biosimilars.

Regence: Biosimilar Adoption Leads to $37 Million Reduction in Annual Spending

November 28th 2022

By Skylar Jeremias

Article

Regence found that implementing strategies to increase its biosimilar adoption rate reduced spending on specialty drugs by $37 million annually. The organization is the latest example of how biosimilar use has contributed to significant savings.

Dr Ryan Haumschild Explains How Technology Can Help Practices Juggle Multiple Biosimilars

November 20th 2022

By Skylar Jeremias

Video

Technology utilizing electronic medical records pathways can be useful for practices struggling to manage multiple biosimilars for the same reference product, according to Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute.

Administration for Pegfilgrastim Biosimilars Should Minimize Clinic Visits, Consider Patients’ Preferences

November 19th 2022

By Deana Ferreri, PhD

Article

A review explored the 3 main administration options for pegfilgrastim biosimilars, finding that providers should consider the ease and frequency to which patients will need to travel to a clinic for administration as well as their preferences when choosing a mode of administration.

AMCP Nexus Abstracts Investigate Adoption, Budget Impact of Biosimilars

November 8th 2022

By Skylar Jeremias

Article

Abstracts presented at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting explored the adoption of infliximab biosimilars, utilization patterns of bevacizumab biosimilars in ophthalmology and oncology settings, and the budget impact of transferring patients to a natalizumab biosimilar from the originator.

AAM Report: Biosimilars, Generics Generated Billions of Dollars in Savings in 2021

November 1st 2022

By Skylar Jeremias

Article

Biosimilar and generic drugs accumulated $373 billion in savings in 2021, $7 billion of which can be attributed to biosimilars alone, according to a report from the Association for Accessible Medicines (AAM).